Title: Hormonal-based male contraceptive moves ahead.

POPLINE Document Number: 281903

Source citation:

Contraceptive Technology Update, 2005 Feb;26(2):[2] p..

Abstract:

Clinical trials for a male contraceptive that is a combination of progesterone and testosterone are expected to begin this year. “We have a protocol for one agent that we’re going to start in clinical trials this year for the National Institutes of Health [NIH],” says Michael Rosenberg, MD, MPH, clinical professor of obstetrics/gynecology and epidemiology at the University of North Carolina-Chapel Hill and president of Health Decisions also in Chapel Hill. The U.S. trials are planned to be Phases I and II studies to look at the pharmacokinetics and effectiveness of a combination of testosterone and nestorone, which is a long-acting progestin that also has been tested in women, he reports. The contraceptive likely will be administered in two pills to about 50 male volunteers, he says. While surveys show men are very interested in having a male contraceptive and might prefer an oral contraceptive, the problem is that hormonal-based contraceptives can cause unpleasant side effects, experts say. (excerpt)

Keywords:

United States
Summary Report
Men
Research and Development
Male Contraception
Progesterone
Testosterone
Side Effects
Safety
North America
Americas
Developed Countries
Demographic Factors
Population
Technology
Economic Factors
Contraception
Family Planning
Progestational Hormones
Hormones
Endocrine System
Physiology
Biology
Androgens
Treatment
Public Health
Health